Efficacy of either PD-1 inhibitor monotherapy or combined PD-1 inhibitor and ipilimumab (an anti-CTLA-4 monoclonal antibody) in patients with disease metastatic uveal melanoma.

Trial Profile

Efficacy of either PD-1 inhibitor monotherapy or combined PD-1 inhibitor and ipilimumab (an anti-CTLA-4 monoclonal antibody) in patients with disease metastatic uveal melanoma.

Completed
Phase of Trial: Phase III

Latest Information Update: 21 Sep 2017

At a glance

  • Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
  • Indications Uveal melanoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 21 Sep 2017 New trial record
    • 01 Sep 2017 Results assessing the efficacy of of either PD-1 inhibitor Pembrolizumab and Nivolumab monotherapy or combined PD-1 inhibitor and ipilimumab in patients with disease metastatic uveal melanoma, were published in the European Journal of Cancer.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top